Advertisement

Topics

NewLink Genetics to Host Its Second Quarter 2015 Earnings Conference Call on July 31, 2015

20:00 EDT 23 Jul 2015 | Globe Newswire

AMES, Iowa, July 24, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease products to improve the lives of  patients, reported that it will release its second quarter 2015 financial results on Friday, July 31, 2015.  The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.

NewLink’s senior management team will host the conference call, which will be open to all listeners.  There will also be a question and answer session following the prepared remarks.

Access to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call.    A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 94565879.  The replay will be available for two weeks from the date of the call. 

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. Our portfolio of product candidates is poised to further cancer-treatment research.  NewLink Genetics is actively researching a unique, multifaceted immuno-oncology treatment strategy based on its HyperAcute® Immunotherapies, which are designed to educate patients’ natural defenses to target cancer directly, and IDO Pathway Inhibitors, which act either alone or in combination with other treatment options to prevent tumor cells from evading the immune response.  NewLink’s Ebola vaccine candidate is being tested in advanced clinical trials in Africa.  For more information, please visit http://www.newlinkgenetics.com.

Corporate Contact:
Jack Henneman, Chief Financial Officer
515-598-2561
Investor@Linkp.com

Investors:
Donna LaVoie or Kristina Coppola
LaVoieHealthScience
617-374-8800 X105/7

Media:
David Connolly
LaVoieHealthScience
617-374-8800 X108
dconnolly@lavoiehealthscience.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "NewLink Genetics to Host Its Second Quarter 2015 Earnings Conference Call on July 31, 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...